Contact Us

Committed to Transforming Treatment

of Nasal Obstruction

Each year, more than three million Americans see a physician for symptoms resulting from nasal obstruction and nearly one million procedures are performed to alleviate these symptoms.

Spirox is focused on developing minimally invasive technologies to improve the quality of life for patients with nasal obstruction.

Patents: The following U.S. patents apply to Spirox™ products, including but not limited to the Latera™ System: US 2014-0243975; US 2015-0012090; and US 2016-0058556. Other patents pending and issued, including US 7,780,730; US 8,133,276; and US 8,784,488. This page is intended to serve as notice under 35 U.S.C. § 287(a).

Duke Rohlen

Chief Executive Officer

20+ years of experience as a medical device company executive

Founder/CEO, CV Ingenuity; CEO, Advanced Cardiac Therapeutics; President, FoxHollow; VP Business Development, Lumend

Stanford BA, Harvard MBA

Doug Koo

Chief Financial Officer

22+ yrs of CFO experience (CV Ingenuity, Ajax Vascular, TauTona)

UCSD BS, Stanford MBA

Scott Baron

VP of Research & Development

15+ yrs. R&D/Ops experience (Acclarent, Abbott Vascular, Lockheed)

Stanford BSME

Matt Brokaw

VP of Marketing and Sales

15+ yrs. medtech experience (Acclarent, Sonitus, Guidant)

Williams BA, Stanford MBA




Don Gonzales, MD

Co-Founder, Chief Medical Officer

Founder, Entrigue Surgical and Mimosa Medical

ENT Trained Surgeon (Cornell Medical School, Tulane Residency)

Mike Rosenthal

Chief Operating Officer

19+ yrs. R&D/Ops experience (CardioGenesis, FoxHollow, Avinger)

Stanford BSME

Bill Beasley

SVP of Manufacturing and Operations

12+ yrs. Med Tech Ops/Exec experience (R2 Tech, FoxHollow, Neodyne Biosciences)
Notre Dame BS Life Sciences



Contact Us

Fill out the form below to get more information on Spirox
* indicates required

Spirox, Inc.

3475 Edison Way, Suite O

Menlo Park, CA 94025

Duke Rohlen


Duke has over 20 years of experience as an executive in medical device companies. Prior to Spirox, Duke served as CEO of Advanced Cardiac Therapeutics, Founder and CEO of CV Ingenuity (acquired by Covidien/Medtronic), President of FoxHollow Technologies (acquired by ev3/Medtronic), entrepreneur-in-residence for Alta Partners, and in other senior management positions. Duke received an M.B.A. from Harvard Business School and a B.A. from Stanford University.


Aftab R. Kherani, MD

Dr. Kherani joined Aisling Capital in 2008 and currently serves as a Partner. Previously, Dr. Kherani was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices for two years.  Prior to McKinsey, Dr. Kherani was a Chief Resident in General Surgery at Duke University Medical Center, and completed a two-year post-doctoral research fellowship at Columbia University, College of Physicians & Surgeons.  Dr. Kherani received his M.D., B.S. in Biology, and A.B. in Economics from Duke University.


Ron Kuppersmith, MD, FACS

Dr. Kuppersmith is an otolaryngologist-head and neck surgeon and a faculty member of the Texas A&M Health Science Center College of Medicine. He has served as the President of the American Academy of Otolaryngology-Head and Neck Surgery, as President of the Texas Association of Otolaryngology-Head and Neck Surgery, and on the Board of Trustees of the College Station Medical Center. Dr. Kuppersmith attended the University of Michigan in Ann Arbor for his undergraduate degree and for medical school, and completed his residency in Otolaryngology-Head and Neck Surgery at Baylor College of Medicine. He also received his M.B.A. from the University of Washington in Seattle.


Jim Momtazee

Jim Momtazee joined KKR in 1996 and is Head of the Health Care industry team and on the Investment Committee of KKR's Americas Private Equity business. He currently serves on the board of directors of Air Medical Group Holdings, Arbor Pharmaceuticals, BridgeBio, PRA Health Sciences and Signostics.  He was also involved in the investments in HCA and Jazz Pharmaceuticals. Prior to joining KKR, Mr. Momtazee was with Donaldson, Lufkin & Jenrette where he worked on a broad range of corporate finance, mergers and acquisitions, and merchant banking transactions. He holds an A.B. and M.B.A from Stanford University.


Tony Natale, MD

Dr. Natale is a General Partner at Aperture Venture Partners.  He has invested across a number of therapeutic areas, and also has been a founder and director of several venture-backed life sciences companies. Dr. Natale trained in General Surgery and Otolaryngology/Head and Neck Surgery at the University of Connecticut and Hartford Hospital, and holds a B.A., Phi Beta Kappa, from the University of Virginia, an M.D. from the University of Florida College of Medicine and an M.B.A. from Yale University’s School of Management.


Camille Samuels

Cami Samuels joined Venrock as a Partner in 2014 and focuses on healthcare with an emphasis on biotech and consumer health.  Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade, and served as a board observer for several companies.  Before Versant, she was responsible for business development at Tularik, worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting.  Cami earned her Bachelor’s degree in Biology from Duke University and an M.B.A. from Harvard Business School, where she graduated as a Baker Scholar.


Stacy Enxing Seng

Stacy Enxing Seng is a Member of the Board of Directors for Sonova Holding AG, Hill-Rom and Solace Therapeutics. Prior to the Medtronic acquisition of Covidien, Enxing Seng served as an Executive in Residence as well as the President, Vascular Therapies, for Covidien. Stacy joined Covidien in July 2010 through the $2.6B ev3 acquisition where she was a founding member and executive officer responsible for leading ev3's Peripheral Vascular Division from inception. She has also held various positions at Boston Scientific Corporation, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. Stacy received a M.B.A. from Harvard University and has a B.A from Michigan State University.


Our Physician Advisors are leaders in otolaryngology, and play a key role in advancing our mission through active collaboration and regular strategic guidance.

Ron Kuppersmith, MD, MBA

Board of Directors

Texas A&M Health Science Center, College Station, TX

Past President, AAO-HNSF

Marvin Fried, MD

Scientific Advisor

Albert Einstein College of Medicine, New York, NY

Past President, ARS

Sam Most, MD

Scientific Advisor

Stanford University,

Stanford, CA

Board of Directors, AAFPRS

Iyad Saidi, MD, PhD

Co-Founder, Scientific Advisor

Metropolitan ENT and Facial Plastic Surgery, Alexandria, VA


Brent Senior, MD

Scientific Advisor

University of North Carolina,

Chapel Hill, NC

Past President, ARS

Abtin Tabaee, MD

Scientific Advisor

Weill Cornell Medical College,
New York, NY

Dean M Toriumi, MD

Scientific Advisor

University of Illinois at Chicago,
Chicago, IL

Past President, AAFPRS


Sources: Shemirani et al. Ann Allergy Asthma Immunol. 2008; 101:5932-598. Spirox data on file.


©2016 Spirox, Inc. All rights reserved. MKT00480 Rev. C

Spirox and Latera and its logos are trademarks of Spirox, Inc.